Open-Systems-Pharmacology · osp-reports-creator · Jul 14, 2026 · Jul 14, 2026
diff --git a/...ation-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_AUC_predictedVsObserved.png b/...ation-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_AUC_predictedVsObserved.png
diff --git a/...ation-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_AUC_residualsVsObserved.png b/...ation-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_AUC_residualsVsObserved.png
diff --git a/...tion-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_predictedVsObserved.png b/...tion-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/...tion-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_residualsVsObserved.png b/...tion-of-ugt-mediated-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_residualsVsObserved.png
diff --git a/...8_section_atazanavir-raltegravir-ddi/comparison_time_profile_Krishna_2016_2.png b/...8_section_atazanavir-raltegravir-ddi/comparison_time_profile_Krishna_2016_2.png
diff --git a/...008_section_atazanavir-raltegravir-ddi/comparison_time_profile_Neely_2010_3.png b/...008_section_atazanavir-raltegravir-ddi/comparison_time_profile_Neely_2010_3.png
diff --git a/...s/008_section_atazanavir-raltegravir-ddi/comparison_time_profile_Zhu_2010_4.png b/...s/008_section_atazanavir-raltegravir-ddi/comparison_time_profile_Zhu_2010_4.png
diff --git a/...enamic-acid-dapagliflozin-ddi/comparison_time_profile_Kasichayanula_2013a_5.png b/...enamic-acid-dapagliflozin-ddi/comparison_time_profile_Kasichayanula_2013a_5.png
diff --git a/DDI_Qualification_UGT/report.md b/DDI_Qualification_UGT/report.md
@@ -1,9 +1,9 @@
 # UGT DDI Inhibition Qualification 
 
-| Version                         | 2.0-OSP12.3                                                   |
+| Version                         | 2.0-OSP13.0                                                   |
 | ------------------------------- | ------------------------------------------------------------ |
 | Qualification Plan Release      | [https://github.com/Open-Systems-Pharmacology/Qualification-DDI-UGT/releases/tag/v2.0](https://github.com/Open-Systems-Pharmacology/Qualification-DDI-UGT/releases/tag/v2.0) |
-| OSP Version                     | 12.3                                                          |
+| OSP Version                     | 13.0                                                          |
 | Qualification Framework Version | 3.7                                                          |
 
 This qualification report is filed at:
@@ -210,7 +210,7 @@ In the plots,
 |573    |Atazanavir, 400 mg, PO, MD OD (8 days)                                             |Raltegravir, PO   |1.44                |1.72               |0.84               |1.12                 |1.37                |0.82                |Neely 2010          |
 |575    |Atazanavir, 400 mg, PO, MD OD (9 days)                                             |Raltegravir, PO   |1.42                |1.67               |0.85               |1.33                 |1.16                |1.15                |Krishna 2016        |
 |579    |Atazanavir, 400 mg, PO, MD BID (14 days)                                           |Raltegravir, PO   |1.57                |1.54               |1.02               |1.39                 |1.39                |1.00                |Zhu 2010            |
-|642    |Mefenamic Acid, 500 / 250 mg, PO, MD QID (4 days), with first dose ad loading dose |Dapagliflozin, PO |1.41                |1.51               |0.93               |1.16                 |1.13                |1.02                |Kasichayanula 2013a |
+|642    |Mefenamic Acid, 500 / 250 mg, PO, MD QID (4 days), with first dose ad loading dose |Dapagliflozin, PO |1.42                |1.51               |0.94               |1.16                 |1.13                |1.03                |Kasichayanula 2013a |
 
 <br>
 <br>

diff --git a/DDI_Qualification_UGT/report.pdf b/DDI_Qualification_UGT/report.pdf